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Abstract Echinocandins and triazoles were proven to be
effective antifungal drugs against invasive fungal infections
(IFI), which may cause significant morbidity and mortality in
immunocompromised patients. The aim of this study was to
compare the efficacy and safety between echinocandins and
triazoles for the prophylaxis and treatment of fungal infec-
tions. PubMed, Embase, and the Cochrane Library were
searched to identify relevant randomized controlled trials
(RCTs) up to July 2014. The quality of trials was assessed
with the Jadad scoring system. The primary outcomes of
interest were treatment success, microbiological success,
breakthrough infection, drug-related adverse events (AEs),
withdrawals due to AEs, and all-cause mortality. Ten RCTs,
involving 2,837 patients, were included, as follows:
caspofungin versus fluconazole (n=1), caspofungin versus
itraconazole (n=1), anidulafungin versus fluconazole (n=1),
micafungin versus fluconazole (n=4), micafungin versus
voriconazole (n=2), and micafungin versus itraconazole (n=
1). Echinocandins and triazoles showed similar effects in
terms of favorable treatment success rate [relative risk
(RR)=1.02, 95 % confidence interval (CI), 0.97–1.08], mi-
crobiological success rate (RR=0.98, 95 % CI, 0.90–1.15),
breakthrough infection (RR=1.09; 95%CI, 0.59–2.01), drug-
related AEs (RR=0.94; 95 % CI, 0.71–1.15), and all-cause
mortality (RR=0.85; 95 % CI, 0.66–1.10) in the prophylaxis
and treatment of fungal infections. Additionally,
echinocandins were more effective than triazoles for prophy-
laxis in patients undergoing hematologic malignancies or
those who received hematopoietic stem cell transplantation
(HSCT; RR=1.08; 95 % CI, 1.02–1.15). Echinocandins sig-
nificantly decreased the AE-related withdrawals rate
compared with triazoles (RR=0.47; 95 % CI, 0.33–
0.67). This meta-analysis revealed that echinocandins
are as effective and safe as triazoles for the prophylaxis
and treatment of patients with fungal infections.
Introduction
Invasive fungal infections (IFI) have emerged as a sig-
nificant cause of morbidity and mortality in immuno-
compromised patients, particularly those with solid tu-
mors or hematological malignancies [1–3], solid organ
transplant [4], human immunodeficiency virus (HIV)
infection [5, 6], and critical illness [7, 8]. Candida
albicans , Cryptococcus neoformans , Aspergillus
fumigatus, and Pneumocystis jirovecii are the most
well-known causes of opportunistic mycosis [9]. The
mortality attributable to candidemia is in the range 30–
50 % [10, 11], and this rate can be as high as 89 % for
invasive aspergillosis [12]. Furthermore, IFI significantly
extends the length of stay in hospital and cause an
additional economic burden. In China, the mean hospi-
talization cost for patients with IFI is US$17,000, which
is significantly higher than that for patients without IFI
(US$8,500; p=0.001) [13], while in Europe, the mean
total cost per patient increases to €8,360 and €15,280
for patients with possible and probable or proven inva-
sive aspergillosis, respectively, compared with patients
without invasive aspergillosis (€57,750; p<0.001) [14].
Fortunately, a range of new antifungals have been
developed and which demonstrated therapeutic potential
over the past two decades. The echinocandins and
triazoles have improved the management of IFI. The
triazoles, including fluconazole, itraconazole, voriconazole,
J.<F. Wang :Y. Xue :X.<B. Zhu :H. Fan (*)
Department of Pharmacy, Sir Run Run Shaw Hospital, School of
Medicine, Zhejiang University, 3 East Qingchun Road,
Hangzhou 310016, Zhejiang, People’s Republic of China
e-mail: hui.fan@yahoo.com
Eur J Clin Microbiol Infect Dis (2015) 34:651–659
DOI 10.1007/s10096-014-2287-4
and posaconazole, have emerged as front-line drugs for the
treatment and prophylaxis of IFI. Fluconazole and
itraconazole were the first-generation triazoles in clinical
practice. Fluconazole plays an excellent role in prophy-
laxis, empirical therapy, and the treatment of invasive
candidiasis. Voriconazole is an effective and safe agent
against the extended spectrum of fungal pathogens.
Posaconazole has a similar antimicrobial spectrum to
voriconazole, with additional activity against zygomycetes
[15]. The echinocandins, such as caspofungin,
micafungin, and anidulafungin, belong to a novel class
of semisynthetic amphiphilic lipopeptides which can
noncompetitively inhibit the synthesis of the β-(1,3)-
D-glucan component of the cell wall of fungi. Also,
the echinocandins have been demonstrated to be safe
and effective in the treatment of disseminated candi-
diasis and invasive aspergillosis, including azole-
resistant strains and biofilms [16]. The Infectious Dis-
eases Society of America (IDSA) guidelines recom-
mend fluconazole and echinocandins (anidulafungin,
caspofungin, or micafungin) as the first-line choice
for invasive candidemia [17]. Voriconazole is recom-
mended as the initial therapy for invasive aspergillo-
sis, while caspofungin, posaconazole, and itraconazole
are alternatives [18].
The purpose of this meta-analysis was to compare the
safety and efficacy of echinocandins with triazoles in
the prophylaxis of fungal infection in high-risk patients
and in the treatment of proven or probable fungal in-
fections. The efficacy end points were treatment suc-
cess, microbiological success, and breakthrough infec-
tion. The safety end points were drug-related adverse




A comprehensive search of PubMed, Embase, and the
Cochrane Central Register of Controlled Trials
(CENTRAL) databases from inception to July 2014
was performed. The search strategy was as follows:
(echinocandin OR caspofungin OR micafungin OR
anidulafungin) AND (triazole OR fluconazole OR
voriconazole OR itraconazole OR posaconazole OR
ravuconazole) AND random*. The results were further
limited to human studies published in English. In addi-
tion, we searched for possible eligible studies in the
references within the retrieved articles, as well as in
review articles.
Study selection
Two reviewers (WJ-F and XY) independently searched the
literature and examined relevant randomized controlled trials
(RCTs) for further assessment. A study was considered
eligible if: (1) it was an RCT, (2) it included patients
with proven or probable fungal infection or those at high
risk of fungal infection, (3) it compared the efficacy or
safety of an echinocandin with a triazole for the prophy-
laxis or treatment of fungal infection. Blinded and open-
labeled trials were included. Trials focusing on pharma-
cokinetic and/or pharmacodynamic profile, dosage form
evaluations, inter-echinocandin or inter-triazole compari-
son, topical use, pediatric or infant studies, as well as
those involving combination therapy were excluded from
further analysis.
Data extraction and qualitative assessment
The same two reviewers conducted data extraction indepen-
dently from eligible trials. In case of any disagreement be-
tween the reviewers, a third reviewer extracted the data and a
consensus was reached. The data extraction form included the
following detailed information: (1) first author, year of publi-
cation, clinical settings; (2) the number of enrolled patients
and intention-to-treat (ITT); (3) antifungal agents and their
doses; (4)outcomes (treatment success rate, microbiological
success rate, breakthrough infection, drug-related AEs, with-
drawals due to AEs, and all-cause mortality). Treatment suc-
cess was defined as an endoscopy grade of 0 (zero) at the end
of therapy for the treatment of esophageal candidiasis, the
resolution of signs and symptoms for the treatment of other
IFI, and the absence of proven, probable, or suspected sys-
temic fungal infection through the end of prophylaxis.
Full-text articles assessed 
for eligibility (n=26)  
Excluded based on titles 
and abstracts (n =238)
Total articles retrieved (n = 296)
Potentially relevant 
articles after duplicates 
removed (n=264)
Duplicates removed(n =32 )




Topical use (n =1)
Combination therapy (n =2)
Pediatric patients or infants (n =3)
Echinocandins vs echinocandins (n =3)
Triazoles vs triazoles (n =3)
Economics analysis (n =3)
Fig. 1 Flow diagram of the selection process for the included studies
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Microbiological success was defined as the eradication of
Candida species and/or Aspergillus species from follow-up
cultures in the treatment trials. Breakthrough infection was
defined as any proven or probable IFI occurring during pro-
phylaxis therapy. Efficacy outcomes (treatment success
rate, microbiological success rate, breakthrough
Fig. 2 Forest plot of RRs for the treatment success rate comparing
echinocandins with triazoles in the prophylaxis and treatment of fungal
infections. a Subgroup analysis based on various echinocandins versus
triazoles. b Subgroup analysis based on prophylaxis and treatment. M-H
Mantel–Haenszel, CI confidence interval
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infection) were assessed in modified ITT (mITT) pa-
tients, while safety outcomes (drug-related AEs, with-
drawals due to AEs, and all-cause mortality) were ana-
lyzed in the ITT population.
The methodological quality of all included trials was
assessed with the Jadad scale [19], which evaluates
randomization, blinding, and the number of reported
dropouts or withdrawals. The score ranges were from
0 to 5 and a trial with a score higher than 2 was
considered a trial of high methodological quality.
Data analysis and statistical methods
Statistical analysis was performed using RevMan (ver-
sion 5.2). Statistical heterogeneity was tested using the
Cochran Q statistics generated from the χ2 test, and
p<0.10 or I2>50 % was judged to be significant. All
outcomes were recorded as dichotomous data. We cal-
culated the pooled risk ratio (RR) and 95 % confidence
intervals (CIs) for all efficacy and safety outcomes
using the Mantel–Haenszel fixed effects or the
random-effects model according to the heterogeneity
analysis. Potential publication bias was estimated by
both a visual funnel plot and the Egger’s test. The
Egger’s test was conducted with STATA software (ver-
sion 12.0).
Results
Included studies and their main characteristics
Figure 1 shows a flow diagram of the process of identification
and selection of the articles included in our study. Our litera-
ture search identified 296 potentially relevant abstracts. By
screening the title and the abstract, 26 full-text articles were
obtained, of which 16 were excluded due to the reasons
mentioned earlier. Finally, ten studies [20–29] with a total of
2,837 patients were included in this analysis.
The main characteristics of the included trials are presented
in Table 1. Among all of the included trials, six studies [20,
22–26] were related to the treatment of proven/probable fun-
gal infections, while four studies [21, 27–29] were involved in
the prophylaxis for high risk of fungal infections. One trial
compared caspofungin with fluconazole [20], one trial com-
pared caspofungin with itraconazole [21], one trial compared
anidulafungin with fluconazole [22], four trials compared
micafungin with fluconazole [23, 24, 27, 29], two trials com-
pared micafungin with voriconazole [25, 26], and one trial
compared micafungin with itraconazole [28]. In terms of
methodology, all of the included trials were deemed to
be of good quality according to the Jadad score (≥2),
with nine trials being multicenter randomized and dou-
ble-blinded, and the last being randomized and open-
labeled.
Fig. 3 Forest plot of RRs for themicrobiological success rate comparing echinocandins with triazoles in the treatment of fungal infections.M-HMantel–
Haenszel, CI confidence interval
Fig. 4 Forest plot of RRs for breakthrough infection comparing echinocandins with triazoles in the prophylaxis of fungal infections. M-H Mantel–
Haenszel, CI confidence interval
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Efficacy outcomes
All of the included studies reported the treatment success
rate in the mITT population. The combined data sug-
gested that there was no significant difference between
echinocandins and triazoles in the treatment success rate
(1,143/1,440 vs. 997/1,306; RR=1.02; 95 % CI, 0.97–
1.08; random effects), but obvious heterogeneity existed
(p=0.03, I2=50 %) (Fig. 2). However, the subgroup
analysis showed that echinocandins were associated with
significantly higher treatment success rates than triazoles
for prophylaxis in patients undergoing hematologic ma-
lignancies or those who received HSCT (671/809 vs.
548/666; RR=1.08; 95 % CI, 1.02–1.15; random effects)
(Fig. 2b). For the treatment of IFI, echinocandins did not
show any better treatment success than triazoles (472/631
vs. 449/640; RR=1.02; 95 % CI, 0.97–1.08; random
effects) (Fig. 2b). Meanwhile, the subgroup analysis in-
dicated that caspofungin (121/187 vs. 124/180; RR=
0.97; 95 % CI, 0.86–1.09; random effects) or micafungin
(928/1,126 vs. 806/1,008; RR=1.01; 95 % CI, 0.96–
1.06; random effects) was not superior to any of the
triazoles (Fig. 2a). The Egger’s test revealed no evidence
of publication bias (p>0.05).
The microbiological success rates were evaluated in
four trials. Candida was the isolated pathogen in three
trials [20, 22, 24] and Aspergillus in the other [26]. The
pooled result showed that the microbiological success rate
of echinocandins was similar to triazoles (286/435 vs.
198/307; RR=0.98; 95 % CI, 0.78–1.23; random effects),
and obvious heterogeneity was present (p=0.005, I2=
77 %) (Fig. 3). There was no significant publication bias
detected when examined by the Egger’s test (p>0.05).
Breakthrough infection after prophylaxis of fungal in-
fections was available in four trials, in which the high-risk
patients suffered from hematologic malignancies or re-
ceived hematopoietic stem cell transplantation (HSCT).
The pooled RR demonstrated that echinocandins were
not significantly different from triazoles in breakthrough
infection (21/717 vs. 19/740; RR=1.09; 95 % CI, 0.59–
2.01; fixed effects), with no statistical evidence of hetero-
geneity among the studies (p=0.43, I2=0 %) (Fig. 4).
There was no significant publication bias detected accord-
ing to the Egger’s test (p>0.05).
Safety outcomes
The rates of AEs considered possibly or probably related to
treatment were reported in seven studies. There was no
significant difference between echinocandins and triazoles
in drug-related AEs (239/1,033 vs. 253/1,072; RR=0.94;
95 % CI, 0.71–1.25; random effects), and obvious
Fig. 5 Forest plot of RRs for drug-related AEs comparing echinocandins with triazoles in the prophylaxis and treatment of fungal infections. M-H
Mantel–Haenszel, CI confidence interval
Fig. 6 Forest plot of RRs for withdrawals due to drug-related AEs comparing echinocandins with triazoles in the prophylaxis and treatment of fungal
infections. M-H Mantel–Haenszel, CI confidence interval
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heterogeneity was found (p=0.006, I2=67 %) (Fig. 5). The
Egger’s test revealed no evidence of publication bias
(p>0.05).
Eight trials showed the proportions of patients who
withdrew from the trials due to drug-related AEs. A signif-
icant difference was found between the echinocandins and
triazoles groups (43/1,226 vs. 95/1,255; RR=0.47; 95 %
CI, 0.33–0.67; fixed effects), and no significant heteroge-
neity among the studies existed (p=0.31, I2=15 %) (Fig. 6).
This result indicates that echinocandins may have lower
rates of patient withdrawal from treatment compared to
triazoles. We recorded no publication bias with the Egger’s
test (p>0.05).
The all-cause mortality during the therapy period was
available in seven trials. However, the causes of death were
rarely related to the study drugs, but, instead, to the progres-
sion of infection or complication. The overall mortality
in the echinocandins group was not significantly differ-
ent from that in the triazoles group (94/1,086 vs. 110/
1,113; RR=0.85; 95 % CI, 0.66–1.10; fixed effects),
without significant heterogeneity among the studies
(p=0.91, I2=0 %) (Fig. 7). There was no publication
bias found based on the Egger’s test (p>0.05).
Discussion
The result of the meta-analysis by Kale-Pradhan et al. sug-
gested that there was no significant difference in efficacy for
the treatment of candidemia or invasive candidiasis between
echinocandins and comparator drugs (liposomal amphotericin
B, amphotericin B, and fluconazole) [30]. Caspofungin, one
of the echinocandins, was also demonstrated to be as effective
as other antifungal agents for the prophylaxis and treatment of
fungal infections [31]. Our pooled analysis of ten RCTs with a
total of 1,469 patients in the echinocandins group and 1,368
patients in the triazoles group showed similar results. It indi-
cated that echinocandins possessed similar effects in terms of
treatment success compared with triazoles in the pro-
phylaxis and treatment of fungal infections. However,
we found that echinocandins were more effective than
triazoles in fungal prophylaxis by the subgroup analysis.
Micafungin is, at present, the only echinocandin ap-
proved for the prophylaxis of fungal infections in HSCT
patients. Xu et al. found that micafungin was associated
with a lower rate of breakthrough infection compared
with fluconazole in the prophylaxis [32]. Nevertheless,
we found that there was no obvious difference in break-
through infection between echinocandins and triazoles
for fungal prophylaxis. The conflict may be due to the
number and type of the included trials. The trial by
Hashino et al. [33] was a retrospective observational
study and the trial by Hiemenz et al. [34] was associ-
ated with combination therapy, which were both exclud-
ed in our analysis. Additionally, the trial by Mattiuzzi
et al. [21] associated with caspofungin was included in
our review.
No differences in drug-related AEs and all-cause
mortality have been found between the echinocandins
and triazoles groups. Both triazoles and echinocandins
have an excellent safety profile and are generally well
tolerated. All triazoles have shown some degree of
hepatotoxicity, ranging from mild hepatitis to cholestasis
and fulminant hepatic failure [35]. Concentrations of
triazoles were deemed to have no relationship with
drug-related AEs. Nausea, vomiting, diarrhea, and hep-
atotoxicity in patients treated with triazoles may hap-
pen in the range of 5–24 % [15]. Besides, there was a
4.0–44.8 % incidence of visual changes in patients
receiving voriconazole [35]. Four included studies re-
ported, in total, seven triazoles-related serious AEs [20,
22, 26]. The serious AEs in the fluconazole arm were
deep-vein thrombosis, elevated levels of hepatic en-
zymes, and fluconazole infusion complicated cellulitis
[20, 22]. The voriconazole-related serious AEs were
ventricular extra systoles, hepatic events, dizziness, and
nausea. All the echinocandins patients were warned of
Fig. 7 Forest plot of RRs for the all-cause mortality comparing echinocandins with triazoles in the prophylaxis and treatment of fungal infections.M-H
Mantel–Haenszel, CI confidence interval
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possible hepatic dysfunction, including hepatic failure
and elevated hepatic enzymes, yet the incidence was
lower than that seen with the comparators [36]. In
addition, rash, phlebitis, and nausea were considered to
be the most frequent AEs of echinocandins. There were
three echinocandins-related serious AEs reported by
three included trials [22, 26], two occurred in the
anidulafungin arm, including atrial fibrillation and sei-
zures [22], and the other was disseminated intravascular
coagulation because of micafungin [26].
We found that the discontinuation rate of echinocandins
due to AEs was significantly lower than that of triazoles
(43/1,226 vs. 95/1,255). In the triazoles groups, the
discontinuation rates due to AEs of fluconazole,
itraconazole, and voriconazole were about 4.3 % [20,
22, 23, 27], 20.1 % [21, 28], and 9.1 % [25, 26],
respectively, while in the echinocandins groups, the
rates of caspofungin, anidulafungin, and micafungin were
2.1 % [20, 21], 0.8 % [22], and 4.2 [23, 25–28], respectively.
Wang et al. [37] found that the pooled risks of treatment
discontinuation due to adverse reactions were 13.4 % for the
amphotericin B formulations, 18.8 % for itraconazole, 2.2 %
for fluconazole, 9.5% for voriconazole, 3.8% for caspofungin,
8.4 % for anidulafungin, and 3.6 % for micafungin.
There were several limitations in this meta-analysis.
First, there was some degree of clinical heterogeneity
between studies. We grouped three different echinocandins
or three different triazoles together, which may lead to hetero-
geneity. Another potential source of heterogeneity was that we
pooled together data from prophylaxis studies and treatment
studies. Second, most of the included studies were associated
with micafungin in the echinocandins group, only two with
caspofungin, and only one with anidulafungin. As a result, the
limited number of studies regarding caspofungin and
anidulafungin may bias the conclusion. Most included trials
were related to fluconazole in the triazoles group, while there
was no RCT comparing posaconazole with echinocandins.
However, Ullmann et al. found that posaconazole was supe-
rior in preventing invasive aspergillosis and reducing the rate
of deaths related to fungal infections compared to fluconazole
[38]. Third, the enrolled patients in the majority of trials were
at high risk of mortality due to illness. When we assessed the
all-cause mortality, we recognized that many patients may
have died due to their original disease but not AEs. Addition-
ally, seven trials included in this meta-analysis were industry-
sponsored, a factor that may generate bias in the assessment of
outcomes.
In conclusion, despite the above limitations, our results
suggested that echinocandins are as effective as triazoles for
the prophylaxis and treatment of patients with fungal infec-
tions. However, echinocandins may be superior to triazoles
for prophylaxis only. Compared to triazoles, echinocandins
were found to be equally safe regarding the incidence rate of
drug-related AEs, despite the fact that withdrawals due to
drug-related AEs was significantly different. Further re-
search is needed in order to compare the efficacy and safety
between posaconazole and echinocandins.
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